Contingency Management Treatment Duration (Duration)

April 5, 2019 updated by: UConn Health
310 alcohol abusing or dependent patients beginning intensive outpatient day treatment at community-based clinics will be randomly assigned to one of four conditions: (a) standard treatment as usual (ST) at the clinic without contingency management (CM); (b) standard treatment with contingency management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted; (c) standard treatment with contingency management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted; or (d) standard treatment with contingency management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted. We expect that contingency management will decrease alcohol use to a greater extent than non-contingency management treatment, and that availability of contingency management for 24 weeks may result in longer term benefits than 12 week exposure to contingency management. This study will be the first to evaluate the effects of probability of winning prizes on response to contingency management.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

310

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • Connecticut
      • Bridgeport, Connecticut, United States, 06604
        • Prospect House
      • Hartford, Connecticut, United States, 06112
        • Alcohol and Drug Recovery Centers, Inc.
      • New Britain, Connecticut, United States, 06050
        • The Hospital of Central Connecticut at New Britain General
      • Waterbury, Connecticut, United States, 06702
        • Morris Foundation
    • Massachusetts
      • Springfield, Massachusetts, United States, 01199
        • Carlson Recovery Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • age > 18 years
  • current DSM-IV diagnosis of alcohol abuse or dependence
  • willing to sign informed consent and able to pass an informed consent quiz

Exclusion Criteria:

  • serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk) on the basis of history or medical examination
  • current DSM-IV diagnosis of opioid dependence
  • in recovery from pathological gambling

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: 1
Standard Treatment
Experimental: 2
Standard Treatment with Contingency Management for 12 weeks with a 0.5 probability of winning prizes for each negative sample submitted
Behavioral: Contingency Management
Prizes given for targeted behavior of abstinence
Experimental: 3
Standard Treatment with Contingency Management for 24 weeks with a 0.34 probability of winning prizes for each negative sample submitted
Behavioral: Contingency Management
Prizes given for targeted behavior of abstinence
Experimental: 4
Standard Treatment with Contingency Management for 24 weeks with a 0.5 probability of winning prizes for each negative sample submitted
Behavioral: Contingency Management
Prizes given for targeted behavior of abstinence

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
longest duration of negative breath samples submitted
Time Frame: active phase and throughout follow-up phase
active phase and throughout follow-up phase

Secondary Outcome Measures

Outcome Measure
Time Frame
subjective reports of alcohol use
Time Frame: baseline and each follow-up
baseline and each follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

UConn Health

Collaborators

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Investigators

  • Principal Investigator: Nancy M Petry, Ph.D., UConn Health

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

February 1, 2008

Primary Completion (Actual)

May 1, 2015

Study Completion (Actual)

May 1, 2015

Study Registration Dates

First Submitted

August 7, 2008

First Submitted That Met QC Criteria

August 7, 2008

First Posted (Estimate)

August 12, 2008

Study Record Updates

Last Update Posted (Actual)

April 9, 2019

Last Update Submitted That Met QC Criteria

April 5, 2019

Last Verified

April 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 08-053-2
  • P60AA003510 (U.S. NIH Grant/Contract)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Alcohol Abuse

Clinical Trials on Contingency Management

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Venezuela

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe